The combination treatment, Egfl6 NAb and a-PD-L1, was associated with (a) a reduced number of intratumoral PMN-MDSCs and TAMs, (b) reduced PMN-MDSC and TAM secretion of IL-10 and Cxcl2, and (c) increased tumor infiltration of antitumor MHC-II+ macrophages. This evidence concerns the gene EGFL6 and neoplasm.